Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of Ocular Side Effects in GBM Patients Treated with Depatuxizumab Mafodotin
NCT03419403Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
A Phase 3 trial of depatuxizumab mafodotin in glioblastoma (GBM), sponsored by AbbVie Inc.. Started Jul 2018; status: terminated.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03419403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419403.